Jenny is the founder and managing partner of Genoa Ventures, where she leverages her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to launch and empower the next generation of category-defying companies at the convergence of technology and biology. She has over a decade of investing experience beginning at Fidelity Biosciences in 2006 as a Kauffman Fellow. After Fidelity, Jenny helped establish the investing function at the Gates Foundation funding companies in genetic engineering, diagnostics, and synthetic biology. Jenny began 5 Prime Ventures in 2014 using the largest life sciences syndicate on AngelList, and achieving one of the highest-performing AngelList syndicates of any sector. Her prior investments include Zymergen, Caribou, Intabio (acquired by Sciex), Accuri (acquired by Becton Dickinson), and Topaz (acquired by Sanofi)